Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2017 4
2018 1
2019 1
2020 2
2021 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
2015/2016 Quality Risk Management Benchmarking Survey.
Waldron K, Ramnarine E, Hartman J. Waldron K, et al. Among authors: ramnarine e. PDA J Pharm Sci Technol. 2017 Sep-Oct;71(5):330-345. doi: 10.5731/pdajpst.2017.007526. Epub 2017 May 15. PDA J Pharm Sci Technol. 2017. PMID: 28512175
PDA Points to Consider: Technical Product Lifecycle Management. Pharmaceutical Quality System Effectiveness for Managing Post-approval Changes.
Authors: Members of the PDA Task Force on Post-approval Changes for Innovation in Availability of Medicines (PAC iAMsm); Ramnarine E, Busse U, Colao M, Edwards J, O'Donnell K, Jornitz M, Munk M, Seymour M, Simianu M, Skeens L, Vinther A. Authors: Members of the PDA Task Force on Post-approval Changes for Innovation in Availability of Medicines (PAC iAMsm), et al. Among authors: ramnarine e. PDA J Pharm Sci Technol. 2017 May-Jun;71(3):252-258. doi: 10.5731/pdajpst.2017.007575. Epub 2017 Feb 14. PDA J Pharm Sci Technol. 2017. PMID: 28196929 Review. No abstract available.
PDA Points To Consider: Technical Product Lifecycle Management: Communication and Knowledge Exchange between Marketing Authorization Holders and Health Authorities.
Authors: Members of the PDA Task Force Post Approval Changes for Innovation in Availability of Medicines (PAC iAM); Ramnarine E, Busse U, Colao M, Edwards J, Jornitz M, Munk M, Seymour M, Simianu M, Skeens L, Vinther A. Authors: Members of the PDA Task Force Post Approval Changes for Innovation in Availability of Medicines (PAC iAM), et al. Among authors: ramnarine e. PDA J Pharm Sci Technol. 2017 Mar-Apr;71(2):163-169. doi: 10.5731/pdajpst.2016.007492. Epub 2017 Jan 15. PDA J Pharm Sci Technol. 2017. PMID: 28089963 Review. No abstract available.
PDA PAC iAM 2017 Survey on Post Approval Change: Is the Regulatory Environment Hindering Much-Needed Innovation in the Pharma Industry?
Authors: Members of the PDA Task Force Post Approval Changes for Innovation in Availability of Medicines (PAC iAM); Ramnarine E, Busse U, Colao M, Edwards J, Follman K, Gale K, Good K, Kiani S, Jornitz M, Munk M, O'Donnel K, Seymour M, Simianu M, Skeens L, Vinther A, Baker D, Levy R. Authors: Members of the PDA Task Force Post Approval Changes for Innovation in Availability of Medicines (PAC iAM), et al. Among authors: ramnarine e. PDA J Pharm Sci Technol. 2017 Sep-Oct;71(5):421-427. doi: 10.5731/pdajpst.2017.008219. Epub 2017 Aug 17. PDA J Pharm Sci Technol. 2017. PMID: 28819050 No abstract available.
11 results